TessArae Delivers Lower Cost Option to Genetic Testing Market
POTOMAC FALLS, Va., Nov. 9 /PRNewswire/ — TessAraeÃ‚® LLC, a global leader in resequencing microarray-based applications, announces the launch of new integrated product solutions for genetic testing of the mutations that underlie human hereditary diseases. The combination of TessArae’s expertise in microarray-based resequencing with novel nucleotide sequence basecalling algorithms and analysis software enables screening for all targeted mutations in multiple genes of a syndrome or disorder simultaneously. This dramatically reduces total testing cost and time-to-result without compromising test accuracy and usability for providers of genetic testing services. The first solution, offered by GeneDx (Gaithersburg, MD), is for Noonan Syndrome, a genetic disorder that causes abnormal development of multiple parts of the body. “Implementation of the custom-designed resequencing solution from TessArae, which simultaneously detects all known mutations and screens for missense mutations in eight genes of the RAS/MAPK pathway, allows GeneDx to offer a more comprehensive test than we could previously, yet at significantly lower cost and with much faster turnaround time,” states John Compton, Ph.D., Co-President and Scientific Director of GeneDx. “Based on the successful integration of this technology into our laboratory workflow, we plan to offer TessArae-developed resequencing microarray-based testing for Periodic Fever Syndromes in the immediate future.” According to Klaus Schafer, M.D., MPH, President and CEO of TessArae, “The human genetic disease testing market represents a new opportunity for us. Our resequencing microarray-based solution is ideally positioned, from both a cost and time-to-result perspective, between conventional and next-gen DNA sequencing technologies, and will generate significant revenue as the genetic testing market grows.”
About TessArae: TessArae’s TessArrayÃ‚® RPM (Resequencing Pathogen Microarray) technology simultaneously detects and identifies numerous viral, bacterial, and fungal pathogens, from clinical, environmental and product samples, enabling characterization — to the strain level — all in a same-day, single-sample, multiple-result test. TessArae’s technology is the only multiplexed genotypic technology that provides direct nucleotide sequence information from pathogen-specific genomic signatures. TessArae has several commercially available products for Research Use Only purposes, including the RPM-Flu Kit for detection and definitive identification of respiratory pathogens, the RPM-TEI Kit for tropical and emerging infections, and the RPM-HFV Kit for whole genome resequencing of HFV hemorrhagic fever viruses. TessArae is based in Potomac Falls, Loudoun County, VA just outside Washington, DC. TessArae products are not intended for in vitro diagnostic use or for patient treatment decisions.
SOURCE TessArae, LLC